logo

For the Inventor, By the Inventor

Sunnyvale, CA, United States of America

Christine E Brotherton-Pleiss

This inventor holds 18 USPTO granted patents and 3 published patent applications and 8 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Hoffmann-La Roche Inc., Roche Palo Alto LLC, Syntex (u.s.a.) Inc.. Active years: 2003-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christine E Brotherton-Pleiss. Retrieved from https://idiyas.com/inventor/christine-e-brotherton-pleiss

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 

% Patents Active = 5.6

 

Average Co-Inventor Count = 4.8

ph-index = 3

Forward Citations = 39(Granted Patents)


Company Filing History:

goldMedal10 out of 5,026 
 
Hoffmann-La Roche Inc.
 patents
silverMedal6 out of 322 
 
Roche Palo Alto LLC
 patents
bronzeMedal2 out of 932 
 
Syntex (u.s.a.) Inc.
 patents

Years Active: 2003-2017

Loading Chart...
Loading Chart...
Areas of Expertise:
Bruton's Tyrosine Kinase
P2X7 Modulators
Sulfonamide Compounds
Carbamate Compounds
Acetamide Derivatives
Dihydropyrimidone Amides
Muscarinic Receptor Antagonists
Non-Nucleoside Reverse Transcriptase Inhibitors
18 patents (USPTO):Explore Patents
1. 9580411 - Substituted sulfonamide compounds (2017-02-28),
2. 9556147 - Inhibitors of bruton's tyrosine kinase (2017-01-31),
3. 9499548 - Inhibitors of bruton's tyrosine kinase (2016-11-22),
4. 9388172 - Substituted carbamate compounds (2016-07-12),
5. 9359337 - Acetamide derivatives (2016-06-07),
6. 9353096 - Substituted phenylcarbamate compounds (2016-05-31),
7. 8940741 - Inhibitors of bruton's tyrosine kinase (2015-01-27),
8. 8889682 - Inhibitors of bruton'S tyrosine kinase (2014-11-18),
9. 8871760 - [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators (2014-10-28),
10. 8742098 - Inhibitors of Bruton's tyrosine kinase (2014-06-03),
11. 8481540 - Inhibitors of bruton's tyrosine kinase (2013-07-09),
12. 8435990 - Dihydropyrimidone amides as P2X7 modulators (2013-05-07),
13. 8163929 - [object Object] (2012-04-24),
14. 8153809 - [object Object] (2012-04-10),
15. 7998969 - Non-nucleoside reverse transcriptase inhibitors (2011-08-16),

Title: Christine E Brotherton-Pleiss: Innovator in Pharmaceutical Compounds

Introduction

Christine E Brotherton-Pleiss is a notable inventor based in Sunnyvale, CA (US). She has made significant contributions to the field of pharmaceuticals, holding a total of 18 patents. Her work primarily focuses on compounds that have the potential to treat various diseases and conditions.

Latest Patents

Among her latest patents, one involves substituted sulfonamide compounds. This invention concerns compounds of a specific formula and their salts, which are detailed in the claims. The compounds are designed to be useful in treating diseases mediated by TRPA1, such as pain. Another significant patent discloses inhibitors of Bruton's tyrosine kinase (BTK). These compounds are aimed at modulating BTK activity and treating diseases associated with excessive BTK activity, including inflammatory and autoimmune diseases like rheumatoid arthritis.

Career Highlights

Christine has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Roche Palo Alto LLC. Her experience in these organizations has contributed to her expertise in developing innovative pharmaceutical solutions.

Collaborations

Some of her notable coworkers include Francisco Javier Lopez-Tapia and Yan Lou. Their collaboration has likely played a role in advancing the research and development of the compounds she has patented.

Conclusion

Christine E Brotherton-Pleiss is a distinguished inventor whose work in pharmaceutical compounds has the potential to impact the treatment of various medical conditions. Her contributions to the field are significant and continue to pave the way for future innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…